Učitavanje...
TCR-Engineered, Customized, Antitumor T Cells for Cancer Immunotherapy: Advantages and Limitations
The clinical outcome of the traditional adoptive cancer immunotherapy approaches involving the administration of donor-derived immune effectors, expanded ex vivo, has not met expectations. This could be attributed, in part, to the lack of sufficient high-avidity antitumor T-cell precursors in most c...
Spremljeno u:
| Izdano u: | ScientificWorldJournal |
|---|---|
| Glavni autor: | |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
TheScientificWorldJOURNAL
2011
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5720046/ https://ncbi.nlm.nih.gov/pubmed/21218269 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1100/tsw.2011.10 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|